Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how antibody-drug conjugates (ADCs) often show more diverse outcomes in real-world settings compared with clinical trials, with varying efficacy and adverse effect profiles. Key practical considerations for pharmacists include appropriate dosing based on patient factors, managing drug interactions, implementing premedication protocols to minimize adverse reactions, and providing comprehensive supportive care. Careful monitoring and individualized patient management are essential for optimal therapeutic outcomes.

EP: 15.Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health

EP: 16.Concluding Remarks: Collaborative Expertise in an Era of Emerging Cancer Therapies

Video content above has been prompted by the following:

In your experience, how do real-world data and patient experiences compare with clinical trial results for approved ADCs?
What practical considerations should pharmacists be aware of when administering ADCs (eg, dosage, premedication regimens, drug interactions, supportive care)?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!

Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care

EP: 1.Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment

EP: 2.Metastatic Breast Cancer Treatment Guidelines and the Nuances of HER2-Low Disease in Clinical Practice

EP: 3.Transforming Breast Cancer Treatment Through ADC-Targeting Mechanisms

EP: 4.How ADC Design Influences Efficacy and Safety

EP: 5.Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer

EP: 6.Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer

EP: 7.Key Considerations for Oncology Pharmacists When Selecting and Sequencing ADC Therapies

EP: 8.Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment

EP: 9.Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies

EP: 10.Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care

EP: 11.Managing ADC Toxicities and Infusion Reactions With Supportive Care Strategies

EP: 12.Monitoring Strategies for Managing ADC Toxicities in mBC

EP: 13.Optimizing ADC Supportive Care Prescribing and AE Management With Institutional Workflows

EP: 14.Discussing ADC Risks, Benefits, and Regimens With Patients

EP: 15.Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health

EP: 16.Concluding Remarks: Collaborative Expertise in an Era of Emerging Cancer Therapies

Newsletter